• Kedalion Therapeutics

  Led · Series A · Aug 2018

  Kedalion Therapeutics is a venture-backed, clinical-stage biotechnology company based in Menlo Park, CA, developing the AcuStream™ digitally connected electromechanical topical ocular delivery device. The AcuStream™ platform is multi-dose, preservative-free and aims to deliver topical ocular therapy reliably, accurately and comfortably while reducing reliance on patient skill and instillation technique. In phase 1 proof-of-concept studies the platform has shown potential for micro-dosing capability and a reduction in delivery dose of an intended therapy (up to an 80% reduction compared to standard eye drops, per company materials). Kedalion cites internal device focus groups, patient comfort testing and other data supporting the technology. The company plans to continue development of the AcuStream™ platform across multiple disease categories, drug classes and compositions, including the treatment of presbyopia. Kedalion recently completed a Series B financing and is collaborating with Novartis as an investor and partner. Kedalion Therapeutics is a venture-backed, clinical-stage biotech focused on developing and commercializing topical ophthalmology therapies based on its proprietary AcuStream platform. The AcuStream technology delivers topical drugs to the eye in a precise and accurate manner, enabling comparable therapeutic effect with up to an 80% reduction in dose compared to standard eye drops. The company intends to use new financing to advance the AcuStream platform through pilot-scale GMP manufacturing and to support advancement of its clinical programs. Management highlighted the platform's potential to improve patient comfort, convenience, compliance, and adherence with therapies, and to generate additional clinical data. Kedalion is based in Menlo Park, California.

• Verana Health

  Participated · Series C · Jul 2018

  Verana Health aggregates de-identified electronic health record data from more than 20,000 clinicians to create high-quality real-world evidence datasets for the life-sciences industry. Its AI-powered curation technology structures and validates data in ophthalmology, urology, and neurology, and, through its merger with COTA, now expands deeply into oncology. The combined company accesses more than 95 million patient records, including over 10 million oncology patients, and partners with an extended network of 30+ academic medical centers. These datasets support biopharma customers across clinical trial design, regulatory submissions, health economics and outcomes research, and market-access work, while also offering advisory services for clinicians’ MIPS submissions. The integration of COTA’s high-fidelity oncology data is expected to speed up data processing and deliver ready-to-analyze datasets to research teams. Verana Health currently serves 17 of the world’s top 20 biopharma companies, underscoring strong commercial traction. The newly raised capital will fund platform expansion and deeper clinical data capabilities. No revenue figures or profitability metrics were disclosed in the article.

• ViewPoint Therapeutics

  Participated · Series B · Mar 2018

  ViewPoint Therapeutics is a preclinical-stage biotech focused on discovering and developing small-molecule crystallin stabilizers to prevent and treat cataracts and presbyopia. Its lead candidate, VP1-001, is a small molecule targeting α-crystallin and is active in preclinical models of age-related cataracts. The company plans to use proceeds from the Series B to advance VP1-001 through clinical proof-of-concept studies in patients with cataracts and presbyopia and to progress second-generation compounds from ongoing medicinal chemistry efforts. ViewPoint was founded in 2014 based on research from the University of Michigan and Washington University in St. Louis and maintains a Scientific Advisory Board with expertise in protein misfolding and crystallin biology. The company emphasizes a non-surgical approach to vision loss and positions its program as potentially disruptive to the current surgical paradigm for cataracts. Financially, ViewPoint has closed a $35 million Series B to fund these development plans. ViewPoint Therapeutics is focused on developing small-molecule crystallin stabilizers to prevent or treat cataracts, presbyopia, and other disorders of aging linked to protein misfolding. Its lead candidate, VP1-001, is a small molecule active in preclinical models of age-related cataracts identified through target-based screening and optimization. The company is advancing second-generation compounds from ongoing medicinal chemistry efforts. ViewPoint plans to use recent funding to support preclinical proof-of-concept experiments for VP1-001 and to progress its chemistry program. The company was co-founded in 2014 and is based in San Francisco, CA. Leadership includes co-founders Dr. Jason Gestwicki, Dr. Leah Makley (CSO), and Ed Hurwitz (Executive Chairman).

No current team members are available.